Qilian International Holding GroupQLI
QLI
Ticker changed
QLI changed its ticker symbol to BGM
About: Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.
Employees: 298
Financial journalist opinion
Neutral
PRNewsWire
3 months ago
Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.
CHENGDU, China , Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective on October 30, 2024, the Company will change its name to "BGM Group Ltd.

Neutral
PRNewsWire
5 months ago
Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"
CHENGDU, China , Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM".

Neutral
PRNewsWire
7 months ago
Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule
CHENGDU, China , July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.

Neutral
PRNewsWire
7 months ago
Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split
CHENGDU, China , June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively.

Neutral
PRNewsWire
8 months ago
Qilian International plans to adjust industrial investment
JIUQUAN, China , May 17, 2024 /PRNewswire/ -- Qilian International Holdings Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered in China, today announced: In the past two years, Qilian International Holdings Group Limited has encountered significant challenges stemming from the continuous shrinkage in market demand for its oxytetracycline products, coupled with a persistent decline in market prices and escalating environmental protection standards. These factors have collectively led to a substantial increase in the production and operational costs for Qilian International, consequently impairing the profitability of the oxytetracycline industry.

Neutral
PRNewsWire
1 year ago
Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI ) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement. The Company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period.

Charts implemented using Lightweight Charts™